

ERRATA CORRIGE

doi: 10.3324/haematol.13875

In the article by Kroot JJ, Laarakkers CM, Kemna EH, Biemond BJ, Swinkels DW. Regulation of serum hepcidin levels in sickle cell disease. *Haematologica* 2009;94:885-887 a wrong version of Table 1 has been published. Correct version is now presented below.

Table 1. Characteristics of study populations of adult sickle cell disease patients in steady state of their disease.

Gender (M/F)	Age (years)	Transfused PCU (n)	Genotype	BMI (kg/m ²)	Hb (mmol/L)	MCV (fL)	ALT (U/L)	Ferritin (µg/L)	TS (0/0)	CRP (mg/L)	sTfR (mg/L)	Reticulocytes (0/0)	Hepcidin-25 Serum (nmol/L)	Hepcidin-25/Urine (nmol/mmol cr)	Hepcidin-25/Ferritin Serum (pmol/µg)	Hepcidin-25/Ferritin Urine (pmol/mmol cr.µg)	
1	F	24	32	SS [†]	31.9	5.9	92.2	81	4470	39.5	50	7.79	11.00	5.5	1.7	1.2	0.4
2	M	22	15	SS [†]	19.4	6.0	—	21	213	71.7	5	8.93	—	<LLOD	0.1	2.3	<0.5
3	F	52	16	SS	23.9	5.4	118.0 [‡]	23	2051	44.4	8	5.36	10.80	9.5	2.5	4.6	1.2
4	F	45	67	SS [†]	18.9	4.6	85.8	16	108	24.1	<5	5.85	8.80	<LLOD	0.1	4.6	<0.9
5	F	18	2	SS [†]	21.1	6.0	96.2	16	140	42.6	<5	4.85	10.00	<LLOD	0.1	3.6	<0.7
6	F	22	5	SS [†]	21.9	5.2	93.1	14	438	39.6	<5	7.69	19.20	1.5	0.3	3.4	0.7
7	F	33	51	SS	19.8	4.0	90.1	26	210	41.9	10	10.40	17.50	<LLOD	0.1	2.4	<0.5
8	F	45	24	SS	18.0	6.1	99.9	68	739	23.3	<5	5.81	7.50	5.4	1.4	7.3	1.9
9	F	46	11	SS	31.3	5.2	125.0 [‡]	10	293	31.2	12	6.14	13.10	2.4	0.4	8.2	1.4
10	F	19	8	Sβ [‡]	22.5	5.4	64.2	52	180	25.5	10	6.87	8.30	1.2	0.5	6.7	2.8
11	F	41	43	Sβ [#]	19.3	4.9	68.9	49	826	42.0	10	5.50	7.80	7.6	0.6	9.2	0.7
12	F	33	30	Sβ [‡]	24.4	6.0	65.5	7	392	21.8	6	7.96	6.30	1.2	0.5	3.1	1.3
13	F	24	n.a.	SC	21.2	5.9	74.7	7	40	23.5	<5	4.03	3.00	<LLOD	0.1	12.5	<2.5
14	M	32	19	SC	27.6	8.6	85.7	26	91	32.8	<5	2.72	2.70	1.4	0.1	15.4	1.1
15	F	29	4	SC	22.8	6.6	73.1	13	65	21.6	<5	2.23	1.60	3.6	0.5	55.4	7.7
16	F	40	n.a.	SC	24.2	7.3	71.1	6	49	18.5	<5	3.15	1.60	1.7	0.2	34.7	4.1
Med.n.a. (range)	33 (18-52)	18 (0-67)	n.a.	22.2 (18.0-31.9)	5.9 (4.0-8.6)	85.8 (64.2-125.0)	19 (6-81)	212 (40-4470)	32.0 (18.5-71.7)	10 (5-50)	5.83 (2.23-10.40)	8.30 (1.60-19.20)	1.5 (<0.5-9.5)	0.4 (0.1-1.7)	5.7 (1.2-55.4)	1.2 (0.4-7.7)	
Control [^]																	
17	M	27	n.a.	AS	26.4	7.8	93.0	16	219	58.5	<5	1.32	0.80	4.6	1.5	21.0	6.8
18	F	37	n.a.	AS	36.3	7.2	65.3	18	66	19.4	22	1.21	1.10	6.0	0.1	90.9	1.5
19	F	61	n.a.	AS	31.2	9.0	81.0	46	132	32.1	<5	1.32	1.00	3.9	2.7	29.6	20.5
20	M	42	n.a.	AS	22.9	8.9	78.5	17	100	19.4	<5	1.40	0.90	5.8	1.4	58.0	14.0
21	F	27	n.a.	AC	21.8	8.5	81.2	19	23	27.3	<5	0.85	0.70	1.4	0.2	60.9	8.7
22	F	38	n.a.	AS	23.3	9.4	76.7	19	20	41.8	<5	2.27	2.20	0.7	0.3	35.0	15.0
23	F	25	n.a.	AS	26.9	8.6	85.4	6	79	36.7	<5	0.76	1.70	1.8	1.5	22.8	19.0
Med.n.a. (range)	37 (25-61)	n.a.	n.a.	26.4 (21.8-36.3)	8.6 (7.2-9.4)	81.0 (65.3-93.0)	18 (6-46)	79 (20-219)	32.1 (19.4-58.5)	5 (5-22)	1.32 (0.76-2.27)	1.00 (0.70-2.20)	3.9 (0.7-6.0)	1.4 (0.1-2.7)	35.0 (21.0-90.9)	14.0 (1.5-20.5)	

[†]Patients 3 and 9 receive maintenance therapy with hydroxyurea; [#], patients with co-inherited β-thalassemia; [^], these controls are race matched carriers and do not have anemia, enhanced hemolysis or inflammation; — indicates lab results are not available; n.a. not applicable; LLOD: lower limit of detection (0.5 nM). CRP is set <5 mg/L when there is no indication of inflammation. Reticulocytes are expressed as the % reticulocytes of the population of red blood cells and reticulocytes. PCU, packed cell units; BMI: body mass index; Hb: hemoglobin; MCV: mean corpuscular volume; ALT: alanine aminotransferase; TS: transferrin saturation; CRP: C-reactive protein; sTfR: soluble transferrin receptor, is a direct measure of the total transferrin receptor in the body and reflects both the cellular need for iron and the rate of erythropoiesis; cr: creatinine. Reference range Caucasian controls hepcidin-25 (n=24), serum 0.5-13.9 nM and urine 0.01-10.6 nmol/mmol creatinine (www.hepcidinanalysis.com); MCV 80-98 fL; serum TS female 15-50%, TS male 20-50%; ferritin female premenopausal 6-80 µg/L; ferritin female postmenopausal 6-190 µg/L; ferritin male 15-280 µg/L; sTfR 0.76-1.76 mg/L.